Shawnalea Frazier
Board of Directors at FireCyte Therapeutics
Shawnalea Frazier
Board of Directors at FireCyte Therapeutics
San Francisco, California
Overview
Work Experience
Director, West Coast Ventures
2023 - Current
AbbVie Ventures, AbbVie's strategic corporate venture capital arm investing in early stage opportunities in oncology, immunology, neuroscience, eye care and aesthetics. https://ventures.abbvie.com
AbbVie is a pharmaceutical company that discovers, develops, and markets medicines.
Raised $15,000,249,999.00.
Board of Directors
2023
Emerging biotechnology company developing novel treatment strategies focused on the role of microglia and neuroinflammation in progressive neurodegenerative diseases of the eye.
Board of Directors
2023
Pioneering biopharmaceutical company unlocking the therapeutic potential of nitrases, a new class of enzymes it discovered. Identification of Synuclein Nitrase is a new target for Parkinson’s disease therapeutics.
Board of Directors (Observer)
2023
• Nov 2023 -- Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients [https://www.trishulatx.com/news/#pr]
Trishula Therapeutics is a biotechnology company that focus on developing cancer medicines.
Board of Directors (Observer)
2023
Biotechnology company pioneering a new class of small molecule therapeutics that modulate the function of RNA to inhibit the production of disease-associated proteins.
Board of Directors (Observer)
2023
• Sept 2023 -- Jnana Therapeutics Presents Additional Data from Phase 1a Clinical Study of JNT-517 at SSIEM Annual Symposium [https://www.jnanatx.com/news/?pag=1]
Jnana Therapeutics develops innovative therapies using a chemoproteomics drug discovery platform.
Raised $207,000,000.00 from AbbVie, Avalon Ventures, Bain Capital Life Sciences, RA Capital Management, Polaris Partners, Pfizer Venture Investments and Versant Ventures.
Corporate Strategy Consultant
2022 - 2023
Immunology biotech startup spun out of Stanford University. • Feb 2023 -- IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy [https://iggenix.com/pressreleases/]
Principal
2020 - 2022
Novo Ventures (US), a Life Science Venture Capital firm investing in private and public biotech companies including therapeutics, medtech and digital health.
Senior Associate
2018 - 2019
Associate
2015 - 2017
Board of Directors (Observer)
2017 - 2022
• May 2021 -- Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial • Apr 2020 -- Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio • May 2017 -- Genoa Pharmaceuticals (fka) Secures $62 Million Series A Financing, Adds to Leadership Team [https://www.avalynpharma.com/news-events/news/]
Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.
Raised $272,500,000.00 from Novo Holdings, F-Prime Capital, SR One, Norwest Venture Partners, RiverVest, Rock Springs Capital, Perceptive Advisors, Surveyor Capital, Pivotal bioVenture Partners and Vida Ventures.
Board of Directors (Observer)
2018 - 2020
• Oct 2020 -- Praxis Precision Medicines announces pricing of upsized initial public offering • July 2020 -- Praxis Precision Medicines announces $110 Million financing • May 2020 -- Praxis Precision Medicines launches with over $100 Million to advance pipeline of high impact therapies for brain disorders [https://investors.praxismedicines.com/press-releases]
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Raised $573,117,750.00 from OCV, Eventide, Irving Investors, Cormorant Asset Management, Novo Holdings, Avoro Capital Advisors, Blackstone Life Sciences, Point72 Ventures, Surveyor Capital and Qatar Investment Authority.